<DOC>
	<DOCNO>NCT00344006</DOCNO>
	<brief_summary>Chlorproguanil-dapsone approve treatment uncomplicated Plasmodium falciparum malaria number country across sub-Sahara Africa , UK 's Medicines Healthcare product Regulatory Agency . CDA combination chlorproguanil , dapsone artesunate , develop public-private partnership Medicines Malaria Venture ( MMV ) , World Health Organisation ( WHO-TDR ) academic partner London School Hygiene Tropical Medicine , University Liverpool Liverpool School Tropical Medicine treatment acute uncomplicated P. falciparum malaria . The combination chlorproguanil-dapsone-artesunate ( CDA ) develop supersede chlorproguanil-dapsone indication , addition artemisinin derivative , artesunate , provide additional population benefit chlorproguanil-dapsone alone . The artemisinins demonstrate rapidly reduce parasite load activity sexual stage P.falciparum lifecycle . The addition second agent chlorproguanil-dapsone combination also protect selection resistant strain P.falciparum . Artemether-lumefantrine available fixed-dose Artemisinin-based Combination Therapy actually available consider gold standard treatment P. falciparum malaria . This study therefore aim demonstrate non-inferiority combination CDA artemether-lumefantrine term efficacy 28-days . The key secondary objective compare Parasite Clearance Times ( PCT ) Fever Clearance Times ( FCT ) CDA artemether-lumefantrine .</brief_summary>
	<brief_title>Chlorproguanil-Dapsone-Artesunate Versus COARTEM For Uncomplicated Malaria</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Chlorproguanil</mesh_term>
	<mesh_term>Proguanil</mesh_term>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Artemether</mesh_term>
	<mesh_term>Artemether-lumefantrine combination</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Dapsone</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<criteria>Inclusion criterion : Acute , uncomplicated P.falciparum malaria , microscopically confirm Temperature screen 37.5oC confirmed history fever within previous 24 hour Weigh 7.5kg Screening haemoglobin ( Hb ) 7g/dl , haematocrit 25 % ( If Hb available screening ) Willingness comply study visit procedure , outline informed consent form Written oral witness consent obtain parent guardian Assent give child age 12 year , addition consent parent guardian Exclusion criterion : Features severe/complicated falciparum malaria Hypersensitivity active substance ( chlorproguanil , dapsone , artesunate , artemether , lumefantrine ) Known allergy biguanides , sulphones , sulphonamides , artemisinin derive product aminoalcohol drug Known history G6PD deficiency Infants history hyperbilirubinaemia neonatal period Use concomitant medication may induce haemolysis haemolytic anaemia WHO ( World Health Organization ) list essential drug Evidence concomitant infection time presentation ( include P. vivax , P. ovale P. malariae ) Any underlying disease may compromise diagnosis evaluation response study medication ( include clinical symptom immunosuppression , tuberculosis , bacterial infection ; cardiac pulmonary disease ) Malnutrition , define child whose weightforheight 3 standard deviation less 70 % median NCHS/WHO normalise reference value Treatment within past three month mefloquine mefloquinesulphadoxinepyrimethamine ; twentyeight day sulphadoxine/pyrimethamine , sulfalene/pyrimethamine , lumefantrine artemether/lumefantrine , amodiaquine , atovaquone atovoquone/proguanil , halofantrine ; 14days chlorproguanil/dapsone , 7days quinine ( full course ) , proguanil , artemisinins , tetracycline doxycycline clindamycin Positive sulphadoxine/pyrimethamine urine screen 'unknown ' antimalarial drug use prior 28days Use investigational drug within 30 day 5 halflives whichever longer Previous participation study Female subject childbearing age , positive pregnancy test screening , give consent take pregnancy test Female subject breastfeed infant duration study</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Malaria CDA COARTEM Africa pediatrics child</keyword>
</DOC>